Prostate Cancer P D:低风险前列腺癌中,直接治疗和积极监测比较

2018-11-28 AlexYang MedSci原创

最近,有研究人员对非常低风险前列腺癌患者的治疗选择进行了研究,并且评估了与医院相关因素的作用。研究包括了2015年和2016年之间鉴定为非常低风险前列腺癌的所有患者((cT1c-cT2a, PSA<10ng/ml, 格林森得分<7,以及<3阳性病灶)。研究人员利用多层次逻辑回归分析调查了直接治疗与积极监测(AS),并评估了患者、肿瘤和医院相关因素的影响。总的来说,2396名患者中

最近,有研究人员对非常低风险前列腺癌患者的治疗选择进行了研究,并且评估了与医院相关因素的作用。

研究包括了2015年和2016年之间鉴定为非常低风险前列腺癌的所有患者((cT1c-cT2a, PSA<10ng/ml, 格林森得分<7,以及<3阳性病灶)。研究人员利用多层次逻辑回归分析调查了直接治疗与积极监测(AS),并评估了患者、肿瘤和医院相关因素的影响。总的来说,2396名患者中的2047(85.4%)患者具有超低风险前列腺癌,并且进行AS。AS患者的比例在不同的医院中范围为33.3到100%。病例组合调整后概率为71%到97%。另外,cT2a vs. cT1c (OR 2.0, 95%CI 1.1-3.6)、2个阳性病灶 vs. 1个阳性病灶(OR 2.8, 95%CI 1.6-4.7)、诊断MRI(OR 2.8, 95%CI 1.5-5.2)、对患者的多学科讨论(OR 2.2, 95%CI 1.1-4.5)、对患者的治疗方案选择的讨论(OR 3.3, 95%CI 1.5-7.4)以及医院的类型(非大学医院 vs. 社区医院:OR 0.5, 95%CI 0.2-0.9)均与直接治疗相关。

最后,研究人员指出,大多数超低前列腺癌风险患者都是进行AS的,但是不同的医院之间具有差异。其中一部分差异可以由患者和肿瘤特性来解释,同样,医院相关的因素也具有作用。他们的研究结果也有利于改善临床实践。

原始出处:

Hanneke Jansen, Inge M. van Oort, George van Andel et al. Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. Prostate Cancer P D. 14 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791559, encodeId=dd9b1e91559fd, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Apr 23 20:40:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953289, encodeId=ca59195328932, content=<a href='/topic/show?id=8dbae512483' target=_blank style='color:#2F92EE;'>#积极监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75124, encryptionId=8dbae512483, topicName=积极监测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Aug 16 20:40:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364423, encodeId=9639136442389, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602090, encodeId=9554160209037, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791559, encodeId=dd9b1e91559fd, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Apr 23 20:40:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953289, encodeId=ca59195328932, content=<a href='/topic/show?id=8dbae512483' target=_blank style='color:#2F92EE;'>#积极监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75124, encryptionId=8dbae512483, topicName=积极监测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Aug 16 20:40:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364423, encodeId=9639136442389, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602090, encodeId=9554160209037, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791559, encodeId=dd9b1e91559fd, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Apr 23 20:40:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953289, encodeId=ca59195328932, content=<a href='/topic/show?id=8dbae512483' target=_blank style='color:#2F92EE;'>#积极监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75124, encryptionId=8dbae512483, topicName=积极监测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Aug 16 20:40:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364423, encodeId=9639136442389, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602090, encodeId=9554160209037, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
    2018-11-30 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791559, encodeId=dd9b1e91559fd, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Apr 23 20:40:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953289, encodeId=ca59195328932, content=<a href='/topic/show?id=8dbae512483' target=_blank style='color:#2F92EE;'>#积极监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75124, encryptionId=8dbae512483, topicName=积极监测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Fri Aug 16 20:40:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364423, encodeId=9639136442389, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602090, encodeId=9554160209037, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 30 03:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
    2018-11-30 sunylz

相关资讯

盘点:前列腺癌与治疗进展

【1】Sci Rep:糖皮质激素能够诱导前列腺癌细胞的治疗抗性相关的应激癌蛋白糖皮质激素受体(GR)在雄激素受体(AR)信号缺陷时,是前列腺癌(PCa)恶化和治疗抗性产生的重要驱使因子。作为一个旁路机制,GR能够激活AR调控的基因表达,尽管GR靶基因能够导致PCa治疗抗性这一结论还未证明。越来越多的证据表明非裔美国(AA)男性不成比例的发展为恶性PCa,他们对GR信号表现为超敏,并与累积的应激

CLIN CANCER RES:SPOP突变/CHD-1缺失前列腺癌与阿比特龙敏感性

CHD1缺失和SPOP突变经常在前列腺癌中共同发生,在去势抵抗性前列腺癌(CRPC)中报道的频率较低。CLIN CANCER RES近期发表了一篇文章,在疾病进展过程中监测CHD1表达情况并评估CHD1 -deleted / SPOP -mutated转移性CRPC(mCRPC)的分子和临床特征。

Pharmacotherapy:前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些?

2018年10月,美国学者发表在《Pharmacotherapy》的一项研究,考察了前列腺癌男性雄激素剥夺治疗(ADT)相关的主要长期副作用风险。

Nat commun:在晚期前列腺癌中,STUB1/HSP70复合物能够控制对雄激素受体靶向治疗的敏感性

蛋白质内稳态(proteostasis)是一种控制癌细胞生存和药物抗性的潜在机制。在晚期前列腺癌中,持续的雄激素受体(AR)变异体的激活能够产生抗雄激素抗性。然而,蛋白质内稳态对下一代抗雄激素抗性的作用以及AR变异体调控的机制仍旧了解很少。最近,有研究人员研究发现,泛素蛋白酶系统(UPS)在恩杂鲁胺/阿比特龙抗性前列腺癌中受到抑制。AR/AR-V7蛋白质内未谈需要E3泛素连接酶STUB1和HSP7

Sci Rep:原发性前列腺癌中,基因组损伤指数与mpMRI和68Ga-PSMA-PET/CT成像特性相关性分析

核磁共振成像(MRI)和前列腺特异性膜抗原(PSMA)-正电子成像术(PET)/计算机断层扫描(CT)-前列腺癌(PCa)成像技术成为评估明显疾病和肿瘤恶化的新兴技术。然而,是否以及由这些成像技术检测到怎样的损伤与PCa基因组特性关联仍旧未知。最近,有研究人员确定了基于染色体拷贝数变异(CNAs)的基因组损伤指数,并将CNAs作为前列腺活检中肿瘤恶化的标记,并且与多参数(mp)MRI和68Ga-P

盘点:前列腺癌进展盘点

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1